A detailed history of Steel Peak Wealth Management LLC transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Steel Peak Wealth Management LLC holds 19,106 shares of NTLA stock, worth $273,215. This represents 0.02% of its overall portfolio holdings.

Number of Shares
19,106
Holding current value
$273,215
% of portfolio
0.02%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$19.72 - $27.36 $376,770 - $522,740
19,106 New
19,106 $392,000
Q1 2024

Apr 17, 2024

BUY
$23.82 - $32.8 $197,920 - $272,535
8,309 New
8,309 $228,000
Q3 2023

Nov 02, 2023

SELL
$31.62 - $45.78 $58,528 - $84,738
-1,851 Reduced 18.22%
8,308 $262,000
Q2 2023

Aug 02, 2023

SELL
$34.58 - $46.03 $119,888 - $159,586
-3,467 Reduced 25.44%
10,159 $414,000
Q1 2023

May 05, 2023

BUY
$33.3 - $44.82 $150,216 - $202,183
4,511 Added 49.49%
13,626 $507,000
Q4 2022

Jan 25, 2023

SELL
$33.21 - $62.69 $132,740 - $250,571
-3,997 Reduced 30.48%
9,115 $0
Q3 2022

Oct 26, 2022

SELL
$53.92 - $71.7 $86,541 - $115,078
-1,605 Reduced 10.91%
13,112 $734,000
Q2 2022

Aug 02, 2022

BUY
$38.49 - $76.21 $13,933 - $27,588
362 Added 2.52%
14,717 $762,000
Q1 2022

May 10, 2022

BUY
$58.27 - $118.99 $381,668 - $779,384
6,550 Added 83.92%
14,355 $1.04 Million
Q4 2021

Jan 31, 2022

SELL
$100.76 - $138.36 $219,556 - $301,486
-2,179 Reduced 21.82%
7,805 $923,000
Q3 2021

Nov 15, 2021

SELL
$132.37 - $176.78 $203,452 - $271,710
-1,537 Reduced 13.34%
9,984 $1.34 Million
Q2 2021

Aug 13, 2021

BUY
$60.88 - $161.91 $65,750 - $174,862
1,080 Added 10.34%
11,521 $1.87 Million
Q1 2021

May 18, 2021

BUY
$46.59 - $83.68 $188,130 - $337,899
4,038 Added 63.06%
10,441 $838,000
Q4 2020

Feb 04, 2021

BUY
$18.83 - $63.53 $120,568 - $406,782
6,403 New
6,403 $348,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.09B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Steel Peak Wealth Management LLC Portfolio

Follow Steel Peak Wealth Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Steel Peak Wealth Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Steel Peak Wealth Management LLC with notifications on news.